Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Daniela Pugliese, Carla Felice, Rosario Landi, Alfredo Papa, Luisa Guidi, Alessandro Armuzzi Inflammatory Bowel Disease Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy Abstract: Significant advances in the management of patients with ulcerative colitis (UC) have been made since...

Full description

Bibliographic Details
Main Authors: Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A
Format: Article
Language:English
Published: Dove Medical Press 2016-02-01
Series:Drug, Healthcare and Patient Safety
Subjects:
ulcerative colitis
refractoriness
anti TNF-alpha
golimumab
Online Access:https://www.dovepress.com/benefitndashrisk-assessment-of-golimumab-in-the-treatment-of-refractor-peer-reviewed-article-DHPS

Internet

https://www.dovepress.com/benefitndashrisk-assessment-of-golimumab-in-the-treatment-of-refractor-peer-reviewed-article-DHPS

Similar Items